Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
Lara C. Czabaniuk, Thousand Oaks, CA (US); Timothy Hopper, Thousand Oaks, CA (US); Jonathan B. Houze, Cambridge, MA (US); Jane Panteleev, Thousand Oaks, CA (US); Gwenaella Rescourio, Thousand Oaks, CA (US); Vincent Santora, Thousand Oaks, CA (US); Haoxuan Wang, Thousand Oaks, CA (US); Ryan D. White, Thousand Oaks, CA (US); Alice R. Wong, Thousand Oaks, CA (US); Yongwei Wu, Thousand Oaks, CA (US); Maxence Bos, Saint-Laurent (CA); John Mancuso, Saint-Laurent (CA); and Ivan Franzoni, Saint-Laurent (CA)
Assigned to AMGEN INC., Thousand Oaks, CA (US); and VIGIL NEUROSCIENCE, INC., Cambridge, MA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US); and Vigil Neuroscience, Inc., Cambridge, MA (US)
Filed on Nov. 30, 2022, as Appl. No. 18/072,505.
Application 18/072,505 is a continuation of application No. 17/302,502, filed on May 4, 2021, granted, now 11,608,344.
Claims priority of provisional application 63/019,772, filed on May 4, 2020.
Prior Publication US 2023/0295170 A1, Sep. 21, 2023
